The virus impacts each person differently and the effectiveness of treatment options also differs from person to person. Rest assured, you or your loved ones will receive the treatment option that may work best for you. At Lehigh Valley Health Network, we are committed to providing our patients and community with the best possible care and treatments. Our research scientists are integrated with our clinical departments for a comprehensive, collaborative approach to research, including COVID-19 clinical trials.
Donation of convalescent plasma for the treatment of other patients with COVID-19
Have you recovered from COVID-19? If so, you may be able to help others who are critically ill from the COVID-19 infection by donating your plasma.
When a person contracts a virus like COVID-19, their immune system creates antibodies to fight the virus. Those who have completely recovered from COVID-19 may have immune-boosting antibodies in their plasma—called “convalescent plasma”—that could be used to treat critically ill COVID-19 patients. This provides a boost to the immune system of the sick patient and may help speed the recovery process.
Miller-Keystone Blood Center is strongly encouraging plasma donations from recovered COVID-19 patients. Plasma (the liquid part of our blood) cannot be manufactured by a pharmaceutical company. Therefore, we are dependent upon donations from recovered patients to ensure that we have a continued supply of this investigational therapy.
A recovered COVID-19 patient can donate plasma 28 days after their symptoms have resolved or 14 days if they receive a negative COVID-19 test. All patients interested in donations will have the same screening performed on all blood product donors.
To become a convalescent plasma donor, contact the MyLVHN Nurse Line at 888-402-LVHN (5846).
LVHN hospitals are using the antiviral medication, remdesivir, to treat patients in the hospital with COVID-19. Lehigh Valley Hospital–Cedar Crest, Lehigh Valley Hospital–Muhlenberg and Lehigh Valley Hospital–Hazleton received the drug through the Pennsylvania Department of Health as part of a federal distribution of 1,200 doses.
Remdesivir is given to a patient through an IV once per day for at least five days. According to the Food and Drug Administration (FDA), remdesivir may help decrease the amount of coronavirus in a person’s body, which may help them get better faster.
According to Timothy Friel, MD, Chair, LVHN’s Department of Medicine, it is the first antiviral medication that has been associated with a faster recovery time in infected COVID-19 patients enrolled in an international randomized, placebo-controlled clinical trial.
With COVID-19, our commitment to safety is more evident than ever. We are taking every possible precaution in every location where we see patients.